ZFAND1

Across TCGA pan-cancer cohorts, ZFAND1 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated ZFAND1 data layer compared with 24 for mass-spec protein and 2 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher ZFAND1 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated ZFAND1 expression acts as an unfavorable survival marker, although some lineages such as LUAD and GBM show a favorable association.

CCRCC, LUAD, and PDAC are the cancer types where ZFAND1 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	DFS	Quartile	III,IV	0.260	0.827	<.001	57	view →
LUAD	OS	Median	III,IV	0.911	0.333	.017	7	view →
PDAC	DFS	Median	All	0.216	0.363	.017	7	view →
GBM	DFS	Quartile	All	0.877	0.584	.040	5	view →
LSCC	OS	Quartile	II,III,IV	0.825	1.000	.039	5	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

ZFAND1–CCRCC (DFS)

Open the CCRCC breakdown →